| Medicare WPS | Billing and Coding: MolDX: FDA-Approved EGFR Tests (55193) | 2024-06-18 |
| Medicare WPS | Billing and Coding: Frequency of Hemodialysis (55703) | 2024-06-18 |
| Medicare WPS | Billing and Coding: MolDX: Predictive Classifiers for Early Stage Non-Small Cell Lung Cancer (57112) | 2024-06-18 |
| Medicare WPS | Billing and Coding: MolDX: Decision Dx-UM (Uveal Melanoma) (57566) | 2024-06-18 |
| Medicare WPS | Billing and Coding: MolDX: Phenotypic Biomarker Detection from Circulating Tumor Cells (58205) | 2024-06-18 |
| Medicare WPS | Billing and Coding: Non-Invasive Fractional Flow Reserve (FFR) for Ischemic Heart Disease (58473) | 2024-06-18 |
| BCBS Highmark Penn CPA/SEPA/WPA/NEPA | Treatment of Abnormal Uterine Bleeding and Uterine Fibroids | 2024-06-17 |
| BCBS Highmark Penn CPA/SEPA/WPA/NEPA | Talimogene Laherparepvec (Imlygic) | 2024-06-17 |
| BCBS Highmark Penn Medicare Advantage | Ziv-aflibercept (Zaltrap) | 2024-06-17 |
| BCBS Highmark Penn Medicare Advantage | Talimogene Laherparepvec (Imlygic) | 2024-06-17 |